In the News
- Aphea.Bio has secured €70 million in series C funding from new and returning investors
- The funding will allow the agritech startup to research and develop its products and expand market reach
- So far, Aphea.Bio has diversified its team and launch its biostimulant seed treatment product, ΛCTIV by Aphea.Bio®
The Story
Aphea.Bio, a Belgium-based agritech company, has announced the successful closing of its Series C Funding round, securing €70 million. The round was led by Innovation Industries, and joined by Korys Investments. The Bill & Melinda Gates Foundation, SFPIM, and BNP Paribas Fortis also supported the funding round. Aphea.Bio also received support from returning investors ECBF, Astanor, AIF and other existing shareholders.
Aphea.Bio is a fully integrated microbial product development company based in Gent, Belgium. The funding will allow Aphea.Bio to further advance research and development in biologicals, scale product launches, expand market reach and commercialise product offerings. The company is dedicated to food security and ensuring a safe and healthy food chain. With a qualified team of scientists and experts, the company is providing novel, science-based solutions to build the agriculture of the future: sustainable, reliable, and profitable.
The company’s partnership with the Gates Foundation will support the development of biostimulant products designed to address the unique needs of smallholder farmers in the foundation’s priority geographies in Sub-Saharan Africa and South Asia.
Isabel Vercauteren, CEO of Aphea.Bio says: “We are excited to have secured Series C Funding, which not only validates our mission to enable sustainable, profitable, and reliable farming, but also propels us toward commercialisation. This investment will allow us to broaden our operations and bring our products to market at a larger scale, so we can address urgent agricultural challenges and meet the needs of farmers worldwide, while at the same time ensuring accessibility and affordability for smallholder farmers in low-income countries.”
Aphea.Bio. has experienced remarkable growth since its launch in 2017. The company has grown into a diverse and talented team of over 50 scientists and industry specialists, and is further expanding its research facilities, with a new pilot plant set to open later this year. Aphea.Bio is also now a Certified B Corporation™, recognised for demonstrating high social and environmental impact standards.
Aphea.Bio has also made significant strides in its product portfolio with the successful launch of ΛCTIV by Aphea.Bio®, a novel biostimulant seed treatment, marking the company’s first entry into the market. Aphea.Bio is now preparing the launch of its first maize biostimulant in 2024, as well as submit its first biofungicide for regulatory approval in the United States and Europe in Q1 and Q3 of next 2024, respectively.
Download the Ebook now
Read also: UAE’s Emirates Development Bank Launches Agritech Loans Programme for Agricultural Financing
